TCRX RSI Chart
Last 7 days
7.0%
Last 30 days
-12.0%
Last 90 days
45.4%
Trailing 12 Months
233.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 17.3M | 16.4M | 16.9M | 21.0M |
2022 | 11.1M | 12.3M | 13.3M | 13.5M |
2021 | 3.3M | 5.6M | 7.9M | 10.1M |
2020 | 0 | 0 | 0 | 1.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 19, 2023 | barberich timothy j | bought | 1,575 | 4.9685 | 317 | - |
Dec 18, 2023 | barberich timothy j | bought | 140,881 | 4.8866 | 28,830 | - |
Dec 14, 2023 | klencke barbara | bought | 25,400 | 5.08 | 5,000 | - |
Jun 02, 2023 | barberich timothy j | bought | 99,563 | 2.6284 | 37,880 | - |
May 31, 2023 | lynx1 capital management lp | sold | -38,804 | 2.51977 | -15,400 | - |
May 31, 2023 | lynx1 capital management lp | sold | -25,148 | 2.5148 | -10,000 | - |
Dec 28, 2022 | silver brian m. | bought | 4,941 | 1.5646 | 3,158 | chief financial officer |
Dec 27, 2022 | silver brian m. | bought | 4,276 | 1.5047 | 2,842 | chief financial officer |
May 18, 2022 | southwell david p | bought | 89,821 | 3.59284 | 25,000 | chief executive officer |
May 11, 2022 | baker bros. advisors lp | bought | 51,349 | 1.9853 | 25,865 | - |
Which funds bought or sold TCRX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | Bank of New York Mellon Corp | sold off | -100 | -97,186 | - | -% |
Apr 24, 2024 | Cambridge Investment Research Advisors, Inc. | new | - | 80,000 | 80,000 | -% |
Apr 17, 2024 | Cannon Global Investment Management, LLC | new | - | 138,950 | 138,950 | 0.37% |
Apr 15, 2024 | ATLAS CAPITAL ADVISORS LLC | reduced | -97.99 | -5,081 | 142 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 2.03 | 5,938,280 | 10,424,900 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | new | - | 353,124 | 353,124 | -% |
Feb 26, 2024 | Virtu Financial LLC | new | - | 107,000 | 107,000 | 0.01% |
Feb 15, 2024 | JANE STREET GROUP, LLC | new | - | 487,516 | 487,516 | -% |
Feb 14, 2024 | 683 Capital Management, LLC | new | - | 251,844 | 251,844 | 0.02% |
Feb 14, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | 288,741 | 514,789 | 0.01% |
Unveiling TScan Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to TScan Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | -8.75 | 6.02 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.0B | 1.8B | -41 | 9.87 | ||||
BMRN | 15.4B | 2.5B | 74.73 | 6.21 | ||||
INCY | 11.6B | 3.7B | 19.41 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 6.0B | 396.6M | -11.37 | 15.16 | ||||
BBIO | 4.4B | - | -6.7 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.22 | 12.57 | ||||
ACAD | 2.8B | 726.4M | -44.9 | 3.79 | ||||
ARWR | 2.7B | 240.7M | -9.23 | 12.18 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.58 | 4.41 | ||||
NVAX | 569.6M | 983.7M | -1.05 | 0.58 | ||||
CRBP | 361.2M | 881.7K | -8.1 | 466.16 | ||||
INO | 247.0M | 4.9M | -1.83 | 50.76 | ||||
IBIO | 6.1M | 2.1M | -0.22 | 2.14 |
TScan Therapeutics, Inc. News
Income Statement (Quarterly) | |||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 |
Revenue | 85.5% | 7,211 | 3,887 | 3,148 | 6,803 | 3,095 | 3,363 | 4,056 | 3,021 | 2,854 | 2,412 | 2,848 | 2,027 | 1,159 | 290 |
Operating Expenses | -0.2% | 28,568 | 28,635 | 27,758 | 29,546 | 21,744 | 19,941 | 19,302 | 19,184 | 17,056 | 18,254 | 13,527 | 9,945 | - | 7,461 |
S&GA Expenses | 4.5% | 6,162 | 5,894 | 6,531 | 7,767 | 6,140 | 4,910 | 4,808 | 4,494 | 4,448 | 4,048 | 2,726 | 2,606 | - | 1,648 |
R&D Expenses | -1.5% | 22,406 | 22,741 | 21,227 | 21,779 | 15,604 | 15,031 | 14,494 | 14,690 | 12,608 | 14,206 | 10,801 | 7,339 | - | 5,813 |
Interest Expenses | -13.2% | 852 | 982 | 969 | 956 | - | 201 | - | - | - | - | - | - | - | - |
Net Income | 14.7% | -19,613 | -22,997 | -24,045 | -22,563 | -18,723 | -16,245 | -15,097 | -16,156 | -14,200 | -15,839 | -10,674 | -7,912 | - | -7,170 |
Net Income Margin | 18.7% | -4.24* | -5.22* | -4.97* | -4.19* | -4.89* | -4.64* | -4.97* | -5.11* | -4.79* | -3.32* | -4.65* | -7.80* | -24.08* | - |
Free Cashflow | -467.3% | -24,235 | 6,598 | -22,442 | -24,425 | -17,387 | -17,426 | -15,260 | -20,655 | -16,591 | -14,493 | -14,618 | -12,916 | - | - |
Balance Sheet | |||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -6.6% | 272 | 291 | 317 | 174 | 199 | 165 | 152 | 168 | 188 | 205 | 130 | 50.00 |
Current Assets | -10.7% | 194 | 218 | 242 | 101 | 124 | 141 | 129 | 146 | 166 | 187 | 110 | 36.00 |
Cash Equivalents | -14.1% | 133 | 155 | 209 | 96.00 | 120 | 137 | 126 | 141 | 166 | 182 | 106 | 35.00 |
Net PPE | -9.9% | 8.00 | 9.00 | 8.00 | 9.00 | 10.00 | 10.00 | 11.00 | 11.00 | 12.00 | 11.00 | 10.00 | 6.00 |
Liabilities | -0.9% | 121 | 122 | 126 | 96.00 | 100 | 49.00 | 21.00 | 23.00 | 27.00 | 31.00 | 31.00 | 33.00 |
Current Liabilities | -10.0% | 30.00 | 33.00 | 35.00 | 14.00 | 17.00 | 17.00 | 17.00 | 18.00 | 21.00 | 23.00 | 21.00 | 17.00 |
Long Term Debt | -7.4% | 27.00 | 29.00 | 30.00 | 30.00 | 29.00 | 29.00 | - | - | - | - | - | - |
LT Debt, Current | 201.5% | 3.00 | 1.00 | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | -7.4% | 27.00 | 29.00 | 30.00 | 30.00 | 29.00 | 29.00 | - | - | - | - | - | - |
Shareholder's Equity | -10.7% | 151 | 169 | 191 | 78.00 | 99.00 | 117 | 132 | 146 | 161 | 174 | - | - |
Retained Earnings | -8.6% | -247 | -228 | -205 | -180 | -158 | -139 | -123 | -108 | -92.16 | -77.96 | -62.12 | -43.53 |
Additional Paid-In Capital | 0.4% | 398 | 397 | 396 | 259 | 258 | 256 | 255 | 254 | 253 | 252 | 2.00 | 1.00 |
Shares Outstanding | 17.7% | 66.00 | 56.00 | 47.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 12.00 | 8.00 | 1.00 | 1.00 |
Float | - | - | - | 74,490 | - | - | - | 49,197 | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | -396.4% | -23,766 | 8,017 | -22,022 | -23,587 | -16,010 | -17,002 | -13,367 | -20,124 | -14,380 | -13,640 | -10,700 | -9,957 | - | - | - |
Share Based Compensation | 11.9% | 1,500 | 1,341 | 1,220 | 1,147 | 1,297 | 1,246 | 1,024 | 984 | 784 | 885 | 503 | 344 | - | - | - |
Cashflow From Investing | 103.1% | 1,913 | -61,414 | -420 | -838 | -1,377 | -424 | -1,893 | -531 | -2,211 | -853 | -3,918 | -2,959 | - | - | - |
Cashflow From Financing | 107.5% | 19.00 | -252 | - | - | 108 | 29,129 | 31.00 | 88.00 | 120 | 90,608 | -686 | 99,626 | - | - | - |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue | ||
Collaboration and license revenue | $ 21,049 | $ 13,535 |
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | Collaboration and license revenue | Collaboration and license revenue |
Operating expenses: | ||
Research and development | $ 88,153 | $ 59,819 |
General and administrative | 26,354 | 20,352 |
Total operating expenses | 114,507 | 80,171 |
Loss from operations | (93,458) | (66,636) |
Other (expense) income: | ||
Interest and other income, net | 7,999 | 1,591 |
Interest expense | (3,759) | (1,176) |
Total other income | 4,240 | 415 |
Net loss | $ (89,218) | $ (66,221) |
Net loss per share, basic | $ (1.36) | $ (2.75) |
Net loss per share, diluted | $ (1.36) | $ (2.75) |
Weighted average common shares outstanding- basic | 65,599,858 | 24,048,267 |
Weighted average common shares outstanding-diluted | 65,599,858 | 24,048,267 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 133,359 | $ 120,027 |
Marketable securities | 58,685 | |
Prepaid expenses and other current assets | 2,193 | 4,100 |
Total current assets | 194,237 | 124,127 |
Property and equipment, net | 7,742 | 10,100 |
Right-of-use assets | 63,492 | 59,102 |
Restricted cash | 5,031 | 5,037 |
Long-term deposit and other assets | 1,647 | 725 |
Total assets | 272,149 | 199,091 |
Current liabilities: | ||
Accounts payable | 2,374 | 2,912 |
Accrued expenses and other current liabilities | 10,716 | 6,838 |
Operating lease liability, current portion | 3,246 | 3,681 |
Deferred revenue, current portion | 10,137 | 3,874 |
Current portion of long-term debt | 3,347 | |
Total current liabilities | 29,820 | 17,305 |
Deferred revenue, net of current portion | 5,622 | |
Operating lease liability, net of current portion | 59,140 | 53,013 |
Long-term debt and accrued interest | 26,700 | 29,290 |
Other long term liabilities | 49 | |
Total liabilities | 121,282 | 99,657 |
Commitments and contingencies (Note 10) | ||
Stockholders' equity (deficit): | ||
Additional paid-in capital | 398,459 | 257,810 |
Accumulated deficit | (247,597) | (158,379) |
Total stockholders' equity | 150,867 | 99,434 |
Total liabilities and stockholders' equity | 272,149 | 199,091 |
Voting Common Stock | ||
Stockholders' equity (deficit): | ||
Common stock | 4 | 2 |
Non-voting Common Stock | ||
Stockholders' equity (deficit): | ||
Common stock | $ 1 | $ 1 |